- Home
- RVSB vs CRBP Comparison
RVSB vs CRBP Comparison
Compare RVSB & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVSB
- CRBP
- Stock Information
- Founded
- RVSB 1923
- CRBP 2009
- Country
- RVSB United States
- CRBP United States
- Employees
- RVSB N/A
- CRBP N/A
- Industry
- RVSB Savings Institutions
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- RVSB Finance
- CRBP Health Care
- Exchange
- RVSB Nasdaq
- CRBP Nasdaq
- Market Cap
- RVSB 115.6M
- CRBP 96.5M
- IPO Year
- RVSB 1993
- CRBP N/A
- Fundamental
- Price
- RVSB $5.75
- CRBP $7.71
- Analyst Decision
- RVSB Buy
- CRBP Strong Buy
- Analyst Count
- RVSB 1
- CRBP 10
- Target Price
- RVSB $7.00
- CRBP $53.56
- AVG Volume (30 Days)
- RVSB 240.3K
- CRBP 219.0K
- Earning Date
- RVSB 07-24-2025
- CRBP 08-05-2025
- Dividend Yield
- RVSB 1.39%
- CRBP N/A
- EPS Growth
- RVSB 27.97
- CRBP N/A
- EPS
- RVSB 0.23
- CRBP N/A
- Revenue
- RVSB $50,239,000.00
- CRBP N/A
- Revenue This Year
- RVSB $12.68
- CRBP N/A
- Revenue Next Year
- RVSB $11.53
- CRBP $150.03
- P/E Ratio
- RVSB $25.00
- CRBP N/A
- Revenue Growth
- RVSB 3.95
- CRBP N/A
- 52 Week Low
- RVSB $3.30
- CRBP $4.64
- 52 Week High
- RVSB $6.59
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- RVSB 60.74
- CRBP 47.66
- Support Level
- RVSB $5.47
- CRBP $6.72
- Resistance Level
- RVSB $5.85
- CRBP $8.71
- Average True Range (ATR)
- RVSB 0.17
- CRBP 0.53
- MACD
- RVSB 0.05
- CRBP -0.15
- Stochastic Oscillator
- RVSB 81.48
- CRBP 40.66
About RVSB Riverview Bancorp Inc
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.